Blood-Brain Barrier Shuttle Antibody Alpha-Synuclein
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for synucleinopathies, such as Parkinson's disease and Lewy body dementia, face challenges in effectively crossing the blood-brain barrier due to the limited penetration of antibodies, hindering their therapeutic efficacy.
Innovation Solution
Development of blood-brain barrier shuttles comprising antibodies, like the 5C1 antibody, coupled with a monovalent binding entity that targets a blood-brain barrier receptor, facilitating the transport of these antibodies across the barrier to bind with alpha-synuclein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies are used to treat synucleinopathies, then therapeutic efficacy against alpha-synuclein aggregates is improved, but penetration across the blood-brain barrier deteriorates
Solution Approach 1:
The patent employs a blood-brain barrier shuttle as an intermediary molecule that mediates the transport of antibodies across the BBB. The shuttle comprises a BBB-targeting moiety (such as transferrin receptor binder or insulin receptor binder) coupled to the therapeutic antibody or antibody fragment, enabling the antibody to cross the barrier without directly interacting with it.
Solution Approach 2:
The invention creates a composite therapeutic agent by combining the BBB-shuttling functionality with the alpha-synuclein-binding antibody. This composite structure integrates two distinct functional elements: the BBB-penetrating component and the therapeutic antibody component, allowing simultaneous achievement of barrier crossing and therapeutic action.
2Object-affected harmful factors
If antibody size is reduced to improve BBB penetration, then blood-brain barrier penetration is improved, but binding affinity to alpha-synuclein may deteriorate
Solution Approach 1:
The patent segments the antibody into smaller functional units that can be independently optimized. It uses antibody fragments (Fab, scFv, Fv) or separate coupling of BBB-shuttling moieties to antibody variable regions, allowing the binding domain to be minimized in size while maintaining affinity, and the shuttling function to be added separately.
Solution Approach 2:
The invention creates multi-functional molecular constructs where a single entity performs multiple roles: the antibody portion maintains high affinity for alpha-synuclein while the coupled BBB-shuttle portion enables barrier penetration. This universal design allows both functions to coexist in one therapeutic agent.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the delivery of therapeutic antibodies to the brain, potentially reducing alpha-synuclein aggregates and improving cognitive function in synucleinopathies by overcoming the barrier limitations.
Implementation Method 1
a monovalent binding entity that binds to a blood-brain barrier receptor; wherein the brain effector entity is coupled to the monovalent binding entity
Data Source
AI summary
The invention provides blood-brain barrier shuttles comprising monoclonal antibody 5C1 and related antibodies linked to a monovalent binding entity for a blood-brain barrier receptor. The 5C1 antibody binds to an epitope within residues 118-126 of alpha-synuclein. The antibodies are useful, for example, for treating and/or diagnosing synucleinopathies including Lewy body diseases, such as Parkinson's disease, diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Alzheimer's and Parkinson's disease comorbidity, and pure autonomic failure, as well as multiple system atrophy (MSA).